1차 출처 기록
결정급탑라인 결과
Quince Therapeutics: A-T 치료를 위한 eDSP의 Phase 3 NEAT 톱라인 결과, 2026년 1분기 예상
회사는 핵심 Phase 3 NEAT 시험(총 105명 참여자)의 등록을 완료했으며, 톱라인 결과가 2026년 1분기에 발표될 예정임을 확인했습니다. 이 시험은 FDA Special Protocol Assessment 하에 진행 중이며, 긍정적인 데이터는 2026년 하반기로 계획된 NDA 제출을 뒷받침할 것입니다.
핵심 사실
출처 발췌
EX-99.1 2 qncx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results Pivotal Phase 3 NEAT clinical trial evaluating lead asset, eDSP, for the treatment of A-T remains on track with topline results expected in first quarter of 2026 SOUTH SAN FRANCISCO, Calif. – November 12, 2025 – Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today provided an update on the company’s development pipeline and reported financial results for the third quarter ended September 30, 2025. Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, said, “Quince remains on track to report